Abstract 4639
Background
AN0025 (previously E7046) is a selective inhibitor of the EP4 receptor and targets macrophages and immunosuppressive cells of myeloid lineage in tumor microenvironment. Preclinical studies have shown potent antitumor activity with AN0025 combining with RT and animal model data suggested antitumor memory T-cell response development by the combination. Neoadjuvant treatment of high-risk rectal cancer provides the platform to test such novel agents to clarify safety and efficacy and provide biopsy and surgical specimens for biomarker analysis.
Methods
This is a multicenter, open-label, Phase 1b study in patients (pts) with poor prognosis locally advanced rectal cancer as defined by standard MRI. This ongoing study enrolled pts into two groups, AN0025 in combination with Long Course Radio Chemotherapy (LCRT), or Short Course Radiotherapy (SCRT) followed by chemotherapy. The dose escalation design comprised 2 dose levels, 250mg and 500mg QD for both SCRT and LCRT. Treatment duration was 10 weeks followed by surgery at week 14-16. Pre-surgery MRI was done at week 11-13. Primary objective was safety and tolerability of AN0025 + CRT.
Results
As of 23 Apr 2019, 27 pts were enrolled. 14 pts were treated in 250 mg cohort with 7 pts in LCRT and in SCRT. No DLT was observed among 13 evaluable pts in this dose level. 500mg cohort is ongoing, 13 pts enrolled. Overall, 18 (66.7%) pts had treatment-related AEs (TRAE), most commonly fatigue (25.9%), diarrhea (14.8%), nausea (11.1%), decreased appetite (11.1%), headache (11.1%), and paraesthesia (11.1%). 2 pts experienced grade 3 TRAEs (diarrhea and fatigue) and 1 pt had serious TRAEs (abdominal pain, vomiting, and fatigue). Median age was 59, 74% were male, 41% had ECOG 1, 56% with T stage T3c-T4b, and 63% were EMVI+. For 250 mg cohort, pre-surgery MRI showed 6/13 pts had downstaging in T stage (3 each in LCRT and SCRT) and mrTRG 1-2 rate was 46% (43% and 50% in LCRT and SCRT respectively). Clinical responses led to 5/13 pts (38%) managed by a watch-and-wait approach.
Conclusions
AN0025 was well tolerated in combination with chemoradiation and preliminary efficacy results are encouraging. Additional safety and efficacy data will be presented.
Clinical trial identification
NCT03152370.
Editorial acknowledgement
Legal entity responsible for the study
Adlai Nortye USA.
Funding
Adlai Nortye USA.
Disclosure
L. Wyrwicz: Honoraria (self), Honoraria (institution): EISAI; Honoraria (self): Adlai Nortye USA. M.P. Saunders: Honoraria (self): Servier, Merck, Amgen, Sanofi. M. Hall: Advisory / Consultancy, Travel / Accommodation / Expenses: Roche, Tesaro, Clovis Oncology; Advisory / Consultancy: AstraZeneca, Amgen. V. Bhagawati Prasad: Full / Part-time employment: Eisai. N. Lautermilch: Full / Part-time employment: Adlai Nortye. M.M. Rashford: Full / Part-time employment: Adlai Nortye. J. Jin: Full / Part-time employment: Adlai Nortye. S. Formenti: Research grant / Funding (self): Bristol-Myers Squibb, Varian, Janssen, Regeneron, Eisai, Merck, Celldex; Honoraria (self): Bristol-Myers Squibb, Varian, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, AstraZeneca, Merck, Viewray, Bayer. R. Glynne-Jones: Advisory / Consultancy: Eisai, Sanofi, Servier, Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
5612 - Evaluation of germ line mutational status among women with triple-negative breast cancer in Russia
Presenter: Elena Shagimardanova
Session: Poster Display session 2
Resources:
Abstract
4142 - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
Presenter: Alberto Ocaña
Session: Poster Display session 2
Resources:
Abstract
1733 - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer
Presenter: Jianfei Fu
Session: Poster Display session 2
Resources:
Abstract
1978 - A Nomogram to Predict Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Blood Indicators
Presenter: Fanrong Zhang
Session: Poster Display session 2
Resources:
Abstract
3062 - Identification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells
Presenter: Sujin Yang
Session: Poster Display session 2
Resources:
Abstract
5274 - Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and its Association with Clinicopathological Parameters in Invasive Breast Cancers
Presenter: Gayathri Devi
Session: Poster Display session 2
Resources:
Abstract
1324 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients
Presenter: Soo Youn Bae
Session: Poster Display session 2
Resources:
Abstract
4877 - Correlation of clinical and pathological features with the tumour microenvironment in DCIS. An institutional experience
Presenter: Ann Eapen
Session: Poster Display session 2
Resources:
Abstract
2471 - Correlation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival
Presenter: Ariadna Gasol Cudos
Session: Poster Display session 2
Resources:
Abstract
2632 - Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer
Presenter: Norio Masumoto
Session: Poster Display session 2
Resources:
Abstract